Université Catholique de Louvain Mont Godinne
Welcome,         Profile    Billing    Logout  
 15 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Doyen, Chantal
NCT00603330: Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function

Recruiting
2
100
Europe
Mesenchymal stem cells
University of Liege, KU Leuven, Maastricht University Medical Center, Ziekenhuis Netwerk Antwerpen (ZNA), University Hospital, Antwerp, University Hospital, Ghent, AZ-VUB, AZ Sint-Jan AV, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, University Hospital of Mont-Godinne, Jolimont Hospital Haine Saint Paul, Queen Fabiola Children's University Hospital
Graft-versus-host Disease, Poor Graft Function, Low Donor T-cell Chimerism
08/24
08/24
Graux, Carlos
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
NCT03852407: Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

Recruiting
2
114
Europe
Thymoglobulin, ATG, Melphalan, alkeran, Fludarabine, Cyclophosphamid, PTCy
University of Liege, Belgian Hematological Society
Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia in Remission, Myeloproliferative Syndrome, Myeloproliferative Disorder, Acute Lymphoid Leukemia in Remission, Multiple Myeloma, Chronic Lymphoid Leukemia, Non Hodgkin Lymphoma, Hodgkin Lymphoma
11/33
11/38
ANDRE, Marc
NCT00433433 / 2005-002765-37: Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma

Active, not recruiting
3
1952
Europe
ABVD q4 weeks, BEACOPP escalated q3 weeks, IN-RT 30 Gy (+ boost 6 Gy residual), Involved-Note Radiation Therapy, FDG-PET scan, F-18 fluorodeoxyglucose positron emission tomography scan
European Organisation for Research and Treatment of Cancer - EORTC, Lymphoma Study Association, Fondazione Italiana Linfomi ONLUS
Lymphoma
12/11
 
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/26
03/27
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen Inc.
Diffuse Large B-cell Lymphoma
05/25
04/27
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
VALYM, NCT04842877 / 2020-005225-81: Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Active, not recruiting
2
141
Europe
Valemetostat tosylate, DS-3201b
The Lymphoma Academic Research Organisation, Daiichi Sankyo
Lymphoma, B-Cell
12/24
10/26
MALIBU, NCT03697512 / 2018-002364-44: Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Active, not recruiting
2
175
Europe
Ibrutinib, Rituximab
International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV
Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
06/27
06/27
PENCIL, NCT06356740: Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus

Not yet recruiting
2
70
Europe
Blood sample, Treatment :Abacavir 600 mg/lamivudine 300 mg, Lupus Impact Tracker questionnaire
Hospices Civils de Lyon
Systemic Lupus Erythematosus
11/28
06/29
KILT, NCT04984837: Study of Lacutamab in Peripheral T-cell Lymphoma

Checkmark KIR3DL2-expressing patients with r/r PTCL
Aug 2021 - Aug 2021: KIR3DL2-expressing patients with r/r PTCL
Recruiting
2
56
Europe
Lacutamab, Gemcitabine, Oxaliplatine
The Lymphoma Academic Research Organisation, Innate Pharma
Peripheral T Cell Lymphoma, Relapse/Recurrence
01/25
01/27
SCLERITA, NCT04789850: Safety and Efficacy of Itacitinib in Adults with Systemic Sclerosis

Recruiting
2
74
Europe
Itacitinib, Placebo
Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis
02/26
02/26
OASIS-II, NCT04802590: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Recruiting
2
194
Europe
Ibrutinib 560 mg, Venetoclax 10 MG Oral Tablet [Venclexta], Venetoclax 50 MG Oral Tablet [Venclexta], Venetoclax 100 MG Oral Tablet [Venclexta]
The Lymphoma Academic Research Organisation, Institute of Cancer Research, United Kingdom
Mantle Cell Lymphoma
03/26
09/31
ABSCESSBIOT, NCT05537909: Role of Gut Microbiota in the Pathophysiology of Aseptic Abscesses

Recruiting
N/A
60
Europe
Biological sample collection
University Hospital, Clermont-Ferrand
Aseptic Abscess Syndrome
12/24
12/25
NCT04220970: Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry

Recruiting
N/A
150
Europe
BIA-ALCL
The Lymphoma Academic Research Organisation
Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL)
06/32
06/32

Download Options